Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 316739, 8 pages
http://dx.doi.org/10.1155/2015/316739
Research Article

Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma

1Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, SI-1000 Ljubljana, Slovenia
2Institute of Oncology Ljubljana, SI-1000 Ljubljana, Slovenia
3Clinical Institute of Occupational Medicine, University Medical Center Ljubljana, SI-1000 Ljubljana, Slovenia

Received 9 July 2015; Revised 4 September 2015; Accepted 6 September 2015

Academic Editor: George Perry

Copyright © 2015 Katja Goričar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. C. Mita, M. M. Mita, S. T. Nawrocki, and F. J. Giles, “Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics,” Clinical Cancer Research, vol. 14, no. 16, pp. 5000–5005, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. A. D. Schimmer, “Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice,” Cancer Research, vol. 64, no. 20, pp. 7183–7190, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Dohi, F. Xia, and D. C. Altieri, “compartmentalized phosphorylation of iap by protein kinase a regulates cytoprotection,” Molecular Cell, vol. 27, no. 1, pp. 17–28, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. B. M. Ryan, N. O'Donovan, and M. J. Duffy, “Survivin: a new target for anti-cancer therapy,” Cancer Treatment Reviews, vol. 35, no. 7, pp. 553–562, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. R. H. Stauber, W. Mann, and S. K. Knauer, “Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential,” Cancer Research, vol. 67, no. 13, pp. 5999–6002, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Nachmias, Y. Ashhab, and D. Ben-Yehuda, “The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer,” Seminars in Cancer Biology, vol. 14, no. 4, pp. 231–243, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Derin, H. O. Soydinç, N. Guney et al., “Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer,” Lung Cancer, vol. 59, no. 2, pp. 240–245, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A. B. Als, L. Dyrskjøt, H. von der Maase et al., “Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer,” Clinical Cancer Research, vol. 13, no. 15, part 1, pp. 4407–4414, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Kawasaki, D. C. Altieri, C.-D. Lu, M. Toyoda, T. Tenjo, and N. Tanigawa, “Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer,” Cancer Research, vol. 58, no. 22, pp. 5071–5074, 1998. View at Google Scholar · View at Scopus
  10. M. Monzó, R. Rosell, E. Felip et al., “A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers,” Journal of Clinical Oncology, vol. 17, no. 7, pp. 2100–2104, 1999. View at Google Scholar · View at Scopus
  11. J. Pizem, A. Cör, L. Zadravec-Zaletel, and M. Popovic, “Survivin is a negative prognostic marker in medulloblastoma,” Neuropathology and Applied Neurobiology, vol. 31, no. 4, pp. 422–428, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. A. I. Sarela, R. C. A. Macadam, S. M. Farmery, A. F. Markham, and P. J. Guillou, “Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma,” Gut, vol. 46, no. 5, pp. 645–650, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Uematsu, I. Ohsawa, T. Aokage et al., “Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index,” Journal of Neuro-Oncology, vol. 72, no. 3, pp. 231–238, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Farnebo, K. Tiefenböck, A. Ansell, L. K. Thunell, S. Garvin, and K. Roberg, “Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients,” International Journal of Cancer, vol. 133, no. 8, pp. 1994–2003, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Zaffaroni and M. G. Daidone, “Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions,” Drug Resistance Updates, vol. 5, no. 2, pp. 65–72, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Kovac, M. Zwitter, and T. Zagar, “Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients,” Radiology and Oncology, vol. 46, no. 2, pp. 136–144, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. R. A. M. Damhuis, C. Schroten, and J. A. Burgers, “Population-based survival for malignant mesothelioma after introduction of novel chemotherapy,” European Respiratory Journal, vol. 40, no. 1, pp. 185–189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Kovac, M. Zwitter, M. Rajer et al., “A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma,” Anti-Cancer Drugs, vol. 23, no. 2, pp. 230–238, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. C. W. Lee, N. Murray, H. Anderson, S. C. Rao, and W. Bishop, “Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia,” Lung Cancer, vol. 64, no. 3, pp. 308–313, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. N. J. Vogelzang, J. J. Rusthoven, J. Symanowski et al., “Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma,” Journal of Clinical Oncology, vol. 21, no. 14, pp. 2636–2644, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Goricar, V. Kovac, and V. Dolzan, “Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma,” Radiology and Oncology, vol. 48, no. 2, pp. 163–172, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. Å. Helland, S. Solberg, and O. T. Brustugun, “Incidence and survival of malignant pleural mesothelioma in Norway: a population-based study of 1686 cases,” Journal of Thoracic Oncology, vol. 7, no. 12, pp. 1858–1861, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Hmeljak, N. Erčulj, V. Dolžan, I. Kern, and A. Cör, “BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients,” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 11, pp. 1641–1651, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Hmeljak, N. Erčulj, V. Dolžan et al., “Is survivin expression prognostic or predictive in malignant pleural mesothelioma?” Virchows Archiv, vol. 462, no. 3, pp. 315–321, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Falleni, C. Pellegrini, A. Marchetti et al., “Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions,” Lung Cancer, vol. 48, no. 2, pp. 211–216, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. G. J. Gordon, M. Mani, L. Mukhopadhyay et al., “Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma,” The Journal of Pathology, vol. 211, no. 4, pp. 447–454, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Kleinberg, A. K. Lie, V. A. Flørenes, J. M. Nesland, and B. Davidson, “Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma,” Human Pathology, vol. 38, no. 7, pp. 986–994, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Zaffaroni, A. Costa, M. Pennati et al., “Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma,” Cellular Oncology, vol. 29, no. 6, pp. 453–466, 2007. View at Google Scholar · View at Scopus
  29. A. Franko, V. Dolzan, V. Kovac, N. Arneric, and M. Dodic-Fikfak, “Soluble mesothelin-related peptides levels in patients with malignant mesothelioma,” Disease Markers, vol. 32, no. 2, pp. 123–131, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. V. Kovac, M. Dodic-Fikfak, N. Arneric, V. Dolzan, and A. Franko, “Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma,” Radiology and Oncology, vol. 49, no. 3, pp. 279–285, 2015. View at Publisher · View at Google Scholar
  31. A. Fawzy, R. Gaafar, F. Kasem, S. S. Ali, M. Elshafei, and M. Eldeib, “Importance of serum levels of angiopoietin-2 and survivin biomarkers in non-small cell lung cancer,” Journal of the Egyptian National Cancer Institute, vol. 24, no. 1, pp. 41–45, 2012. View at Publisher · View at Google Scholar
  32. N. Guney, H. O. Soydine, D. Derin et al., “Serum and urine survivin levels in breast cancer,” Medical Oncology, vol. 23, no. 3, pp. 335–339, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Dobrzycka, B. Mackowiak-Matejczyk, K. M. Terlikowska, B. Kulesza-Bronczyk, M. Kinalski, and S. J. Terlikowski, “Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer,” European Cytokine Network, vol. 24, no. 3, pp. 106–113, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Nigam, A. Chandra, H. R. Kazmi et al., “Expression of serum survivin protein in diagnosis and prognosis of gallbladder cancer: a comparative study,” Medical Oncology, vol. 31, no. 9, article 167, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Q. Ren, H. Y. Zhang, T. Su, X. H. Wang, and L. Zhang, “Clinical significance of serum survivin in patients with pancreatic ductal adenocarcinoma,” European Review for Medical and Pharmacological Sciences, vol. 18, no. 20, pp. 3063–3068, 2014. View at Google Scholar
  36. M. J. Byrne and A. K. Nowak, “Modified RECIST criteria for assessment of response in malignant pleural mesothelioma,” Annals of Oncology, vol. 15, no. 2, pp. 257–260, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Ozimič, J. Hmeljak, and A. Cör, “Survivin expression in response to cisplatin-induced stress,” in Book of Abstracts—7th Conference on Experimental and Translational Oncology, G. Serša, J. Kos, T. L. Turnšek et al., Eds., p. 122, Association of Radiology and Oncology, Portorož, Slovenia, 2013. View at Google Scholar
  38. W. Naumnik, W. Nilklińska, M. Ossolińska, and E. Chyczewska, “Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy,” Folia Histochemica et Cytobiologica, vol. 47, no. 4, pp. 703–709, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Freier, S. Pungs, C. Sticht et al., “High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy,” International Journal of Cancer, vol. 120, no. 4, pp. 942–946, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. S. M. Kennedy, L. O'Driscoll, R. Purcell et al., “Prognostic importance of survivin in breast cancer,” British Journal of Cancer, vol. 88, no. 7, pp. 1077–1083, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Ponnelle, C. Chapusot, L. Martin et al., “Cellular localisation of survivin: impact on the prognosis in colorectal cancer,” Journal of Cancer Research and Clinical Oncology, vol. 131, no. 8, pp. 504–510, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Trieb, R. Lehner, T. Stulnig, I. Sulzbacher, and K. R. Shroyer, “Survivin expression in human osteosarcoma is a marker for survival,” European Journal of Surgical Oncology, vol. 29, no. 4, pp. 379–382, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Vischioni, P. van der Valk, S. W. Span, F. A. E. Kruyt, J. A. Rodriguez, and G. Giaccone, “Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer,” Annals of Oncology, vol. 15, no. 11, pp. 1654–1660, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Reichert, C. Rödel, J. Mirsch et al., “Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma,” Radiotherapy & Oncology, vol. 101, no. 1, pp. 51–58, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. B. Unruhe, E. Schröder, D. Wünsch, and S. K. Knauer, “An old flame never dies: survivin in cancer and cellular senescence,” Gerontology, 2015. View at Publisher · View at Google Scholar
  46. P. N. Span, V. C. G. Tjan-Heijnen, P. Manders, D. Van Tienoven, J. Lehr, and F. C. G. J. Sweep, “High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer,” Breast Cancer Research and Treatment, vol. 98, no. 2, pp. 223–230, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. X. Jia, Y. Gao, D. Zhai et al., “Survivin is not a promising serological maker for the diagnosis of hepatocellular carcinoma,” Oncology Letters, vol. 9, no. 5, pp. 2347–2352, 2015. View at Publisher · View at Google Scholar